CORTINOVIS DIEGO LUIGI

Lee, S., Schulz, C., Baird, A., Prabhash, K., Kowalski, D., Szczesna, A., et al. (2025). A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study). FUTURE ONCOLOGY, 21(14), 1725-1734 [10.1080/14796694.2025.2500915]. Dettaglio

Passarella, G., Canova, S., Abbate, M., Caspani, G., Sala, L., Russo, A., et al. (2025). The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer. DISCOVER ONCOLOGY, 16(1) [10.1007/s12672-025-01826-7]. Dettaglio

Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D., et al. (2025). An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016. LUNG CANCER, 199(January 2025) [10.1016/j.lungcan.2024.108059]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Dettaglio

Facchinetti, F., Camerini, A., Bennati, C., Bordi, P., Carlo, E., Mazzoni, F., et al. (2025). A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020). LUNG CANCER, 204(June 2025) [10.1016/j.lungcan.2025.108580]. Dettaglio